GSK, Pfizer RSV vaccine sales fall in US
GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got one last year.
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
GSK trial proves RSV vaccine efficacy after three full seasons
Arexvy is the world's first approved RSV vaccine and results showed that after a single dose, cumulative efficacy over three full RSV seasons was clinically meaningful.
GSK’s Arexvy vaccine for RSV is approved for Malaysian seniors
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine will be available in October 2024
Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up
A GSK spokesperson said 9 million Americans, or two-thirds of the market, have been vaccinated against RSV with Arexvy and that the company sees opportunities for strong growth in
Pfizer wins bid to invalidate GSK's patents over RSV vaccine
Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV,
U.K. court rules in Pfizer's favor in GSK RSV vaccine dispute: report
Pfizer (PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (GSK) patents for its RSV vaccine. Read more here.
GSK Pharma to expand into oncology, focus on adult vaccines in India
GlaxoSmithKline Pharma is shifting focus to specialty treatments and preventive healthcare, emphasizing adult vaccines and ...
GlaxoSmithKline (GSK) Gets a Hold from Barclays
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.
FiercePharma15h
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
GlaxoSmithKline Pharma to enter oncology market, launch adult vax
GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...
GSK rises Monday, outperforms market
Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...
Mumbai : Cash And Gold Worth ₹29 Lakh Stolen From Retired GSK Employee's Apartment In Byculla
Mumbai: A retired GlaxoSmithKline (GSK) employee, Ashok Shetty, on Monday reported a home burglary involving the theft of ...
J.P. Morgan Reaffirms Their Sell Rating on GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
London South East7d
Glaxosmithkline Share Chat (GSK)
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
FiercePharma1d
In long-acting HIV PrEP access showdown with Gilead, GSK moves to triple Apretude supply for certain countries
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...